{{Rsnum
|rsid=1052717
|Gene=SREBF2
|Chromosome=22
|position=41885425
|Orientation=plus
|GMAF=0.3232
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SREBF2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 30.1 | 45.1 | 24.8
| HCB | 5.1 | 39.4 | 55.5
| JPT | 7.1 | 44.2 | 48.7
| YRI | 0.0 | 12.3 | 87.7
| ASW | 0.0 | 40.4 | 59.6
| CHB | 5.1 | 39.4 | 55.5
| CHD | 7.4 | 41.7 | 50.9
| GIH | 13.9 | 43.6 | 42.6
| LWK | 0.9 | 16.4 | 82.7
| MEX | 5.2 | 34.5 | 60.3
| MKK | 0.0 | 15.4 | 84.6
| TSI | 28.4 | 45.1 | 26.5
| HapMapRevision=28
}}{{PMID|18936756}} Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples.

{{PharmGKB
|RSID=rs1052717
|Name_s=
|Gene_s=SREBF2
|Feature=
|Evidence=PubMed ID:18936756
|Annotation=This SNP in the SREBF2 gene was strongly associated with schizophrenia in German, Danish and Norwegian samples.
|Drugs=
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162355924
}}

{{PMID|18954446|OA=1
}} Significant association of SREBP-2 genetic polymorphisms with avascular necrosis in the Korean population.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1052717
|overall_frequency_n=92
|overall_frequency_d=128
|overall_frequency=0.71875
|n_genomes=49
|n_genomes_annotated=0
|n_haplomes=76
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}